- Home
- SUPN
as 09-17-2025 4:00pm EST
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 2.6B | IPO Year: | 2012 |
| Target Price: | $43.00 | AVG Volume (30 days): | 654.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.14 | EPS Growth: | 1411.53 |
| 52 Week Low/High: | $29.16 - $46.78 | Next Earning Date: | 11-03-2025 |
| Revenue: | $665,125,000 | Revenue Growth: | 5.55% |
| Revenue Growth (this year): | 4.84% | Revenue Growth (next year): | 17.69% |
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mottola Frank | SUPN | SVP, Chief Tech. Ops. Officer | Sep 12 '25 | Sell | $45.87 | 5,000 | $229,350.00 | 15,496 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 8 '25 | Sell | $46.29 | 6,322 | $292,645.38 | 1,111,983 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 5 '25 | Sell | $46.01 | 55,578 | $2,557,143.78 | 1,111,983 | |
| Mottola Frank | SUPN | SVP, Quality, GMP, Ops, IT | Aug 25 '25 | Sell | $44.51 | 14,000 | $623,140.00 | 15,496 | |
| Khattar Jack A. | SUPN | President, CEO | Aug 25 '25 | Sell | $45.00 | 1,000 | $45,000.00 | 1,111,983 | |
| NEWHALL CHARLES W III | SUPN | N/A | Aug 25 '25 | Sell | $45.00 | 1,000 | $45,000.00 | 133,232 | |
| DEC TIMOTHY C | SUPN | Senior Vice-President & CFO | Aug 22 '25 | Sell | $44.49 | 11,780 | $524,092.20 | 1,246 | |
| Khattar Jack A. | SUPN | President, CEO | Aug 22 '25 | Sell | $45.00 | 1,500 | $67,500.00 | 1,111,983 | |
| NEWHALL CHARLES W III | SUPN | N/A | Aug 22 '25 | Sell | $45.00 | 1,412 | $63,540.00 | 133,232 | |
| Hudson Frederick M. | SUPN | N/A | Aug 14 '25 | Sell | $42.26 | 7,457 | $315,132.82 | 46,307 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?
StockStory
13 days ago
1 Cash-Producing Stock to Research Further and 2 We Brush Off
Insider Monkey
16 days ago
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio
StockStory
3 months ago
Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
Argus Research
3 months ago
SUPN: Lowering target price to $33.00
Simply Wall St.
3 months ago
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years
TipRanks
3 months ago
H.C. Wainwright sees potential competition for Sage from Biogen
Zacks
3 months ago
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
Compare SUPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.